Gary L Johnson
Overview
Explore the profile of Gary L Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
6908
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Kalogirou A, East M, Laitinen T, Torrice C, Maffuid K, Drewry D, et al.
Molecules
. 2021 Oct;
26(19).
PMID: 34641454
A focused series of substituted 4-1,2,6-thiadiazin-4-ones was designed and synthesized to probe the anti-cancer properties of this scaffold. Insights from previous kinase inhibitor programs were used to carefully select several...
22.
Zhu H, Ficarro S, Alexander W, Fleming L, Adelmant G, Zhang T, et al.
Anal Chem
. 2021 Oct;
93(41):13791-13799.
PMID: 34606255
Parallel reaction monitoring (PRM) has emerged as a popular approach for targeted protein quantification. With high ion utilization efficiency and first-in-class acquisition speed, the timsTOF Pro provides a powerful platform...
23.
Yesilkanal A, Johnson G, Ramos A, Rosner M
J Biol Chem
. 2021 Aug;
297(4):101128.
PMID: 34461089
Targeted strategies against specific driver molecules of cancer have brought about many advances in cancer treatment since the early success of the first small-molecule inhibitor Gleevec. Today, there are a...
24.
Cheng C, Reis S, Adams E, Fass D, Angus S, Stuhlmiller T, et al.
Sci Rep
. 2021 Aug;
11(1):17029.
PMID: 34426604
Mutations in MAPT (microtubule-associated protein tau) cause frontotemporal dementia (FTD). MAPT mutations are associated with abnormal tau phosphorylation levels and accumulation of misfolded tau protein that can propagate between neurons...
25.
Chang L, Oblinger J, Smith A, Ferrer M, Angus S, Hawley E, et al.
PLoS One
. 2021 Jul;
16(7):e0252048.
PMID: 34264955
Neurofibromatosis Type 2 (NF2) is an autosomal dominant genetic syndrome caused by mutations in the NF2 tumor suppressor gene resulting in multiple schwannomas and meningiomas. There are no FDA approved...
26.
Angus S, Stuhlmiller T, Mehta G, Bevill S, Goulet D, Olivares-Quintero J, et al.
NPJ Breast Cancer
. 2021 May;
7(1):51.
PMID: 33980863
Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2...
27.
Yesilkanal A, Yang D, Valdespino A, Tiwari P, Sabino A, Nguyen L, et al.
Elife
. 2021 May;
10.
PMID: 33973518
Metastasis suppression by high-dose, multi-drug targeting is unsuccessful due to network heterogeneity and compensatory network activation. Here, we show that targeting driver network signaling capacity by limited inhibition of core...
28.
Mehta G, Angus S, Khella C, Tong K, Khanna P, Dixon S, et al.
NPJ Breast Cancer
. 2021 Apr;
7(1):40.
PMID: 33837205
Dysregulation of PI3K/Akt signaling is a dominant feature in basal-like or triple-negative breast cancers (TNBC). However, the mechanisms regulating this pathway are largely unknown in this subset of aggressive tumors....
29.
Fisher M, Shih C, Rhodes S, Armstrong A, Wolters P, Dombi E, et al.
Nat Med
. 2021 Jan;
27(1):165-173.
PMID: 33442015
Neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNs) are progressive, multicellular neoplasms that cause morbidity and may transform to sarcoma. Treatment of Nf1;Postn-Cre mice with cabozantinib, an inhibitor of multiple tyrosine...
30.
Pucciarelli D, Angus S, Huang B, Zhang C, Nakaoka H, Krishnamurthi G, et al.
Mol Cancer Ther
. 2020 Aug;
19(11):2382-2395.
PMID: 32847978
Loss of the tumor suppressor leads to activation of RAS effector pathways, which are therapeutically targeted by inhibition of mTOR (mTORi) or MEK (MEKi). However, therapeutic inhibition of RAS effectors...